Since IN I-PP O 0,5
the DT I-NP O 6,9
receptors NNS I-NP O 10,19
in IN I-PP O 20,22
human JJ I-NP O 23,28
biology NN I-NP O 29,36
mostly RB O O 37,43
consist VBZ I-VP O 44,51
of IN I-PP O 52,54
chiral JJ I-NP I-KP 55,61
molecules, JJ I-NP I-KP 62,71
drug NN I-NP O 73,77
action NN I-NP O 78,84
mostly RB O O 85,91
involves VBZ I-VP O 92,100
a DT I-NP O 101,102
specified JJ I-NP O 103,112
enantiomeric JJ I-NP O 113,125
form. NN I-NP O 126,130

This DT I-NP O 132,136
has VBZ I-VP O 137,140
spurred VBN I-VP O 141,148
the DT I-NP O 149,152
development, NN I-NP O 153,164
especially RB O O 166,176
in IN I-PP O 177,179
the DT I-NP O 180,183
pharmaceutical JJ I-NP O 184,198
industry, NN I-NP O 199,207
of IN I-PP O 209,211
a DT I-NP O 212,213
host NN I-NP O 214,218
of IN I-PP O 219,221
techniques NNS I-NP O 222,232
to TO I-VP I-KP 233,235
secure VB I-VP I-KP 236,242
enantiopure NN I-NP I-KP 243,254
products. NN I-NP I-KP 255,263

Such JJ I-NP O 265,269
methods, NNS I-NP I-KP 270,277
mostly RB O I-KP 279,285
and CC O I-KP 297,300
can MD I-VP O 317,320
typically RB I-VP O 321,330
be VB I-VP O 331,333
cast VBN I-VP O 334,338
in IN I-PP O 339,341
one CD I-NP O 342,345
of IN I-PP O 346,348
two CD I-NP O 349,352
distinct JJ I-NP O 353,361
categories: NNS I-NP O 362,372
synthetic JJ I-NP I-KP 374,383
mechanisms NNS I-NP I-KP 384,394
designed VBN I-VP O 395,403
to TO I-VP O 404,406
produce VB I-VP O 407,414
a DT I-NP O 415,416
single JJ I-NP O 417,423
stereoisomer, NN I-NP I-KP 424,436
or CC O O 438,440
separation NN I-NP I-KP 441,451
techniques NNS I-NP I-KP 452,462
to TO I-VP O 463,465
isolate VB I-VP O 466,473
distinct JJ I-NP O 474,482
enantiomers NNS I-NP I-KP 483,494
from IN I-PP O 495,499
a DT I-NP O 500,501
racemic JJ I-NP O 502,509
mixture. NN I-NP O 510,517

A DT I-NP O 519,520
significant JJ I-NP O 521,532
drawback, NN I-NP O 533,541
for IN I-PP O 543,546
either DT I-NP O 547,553
approach, NN I-NP O 554,562
is VBZ I-VP O 564,566
a DT I-NP O 567,568
dependence NN I-NP O 569,579
on IN I-PP O 580,582
a DT I-NP O 583,584
supply NN I-NP O 585,591
of IN I-PP O 592,594
enantiopure NN I-NP I-KP 595,606
reagents NNS I-NP I-KP 607,615
or CC O I-KP 616,618
substrates NNS I-NP I-KP 619,629
– VBP I-VP O 630,631
synthesis NN I-NP I-KP 632,641
routes NNS I-NP I-KP 642,648
generally RB O O 649,658
utilise JJ I-NP O 659,666
chiral JJ I-NP I-KP 667,673
building NN I-NP I-KP 674,682
blocks NNS I-NP I-KP 683,689
or CC O O 690,692
enantioselective JJ I-NP I-KP 693,709
catalysts NNS I-NP I-KP 710,719
[7,8], VBP I-VP O 720,725
while IN I-PP O 727,732
enantiomer JJ I-NP I-KP 733,743
separation NN I-NP I-KP 744,754
techniques NNS I-NP I-KP 755,765
typically RB O O 766,775
incorporate VBP I-VP O 776,787
chiral JJ I-NP I-KP 788,794
selector NN I-NP I-KP 795,803
molecules NNS I-NP I-KP 804,813
to TO I-VP O 814,816
form VB I-VP O 817,821
chemically RB O O 822,832
distinct JJ I-NP O 833,841
and CC O O 842,845
distinguishable JJ I-NP O 846,861
diastereomeric NN I-NP I-KP 862,876
complexes NNS I-NP I-KP 877,886
[8,9]. VBP I-VP O 887,892

A DT I-NP O 894,895
key JJ I-NP O 896,899
requirement NN I-NP O 900,911
in IN I-PP O 912,914
aiming VBG I-VP O 915,921
to TO I-VP O 922,924
achieve VB I-VP I-KP 925,932
enantiopure NN I-NP I-KP 933,944
products, JJ I-NP I-KP 945,953
irrespective NN I-NP I-KP 955,967
of IN I-PP I-KP 968,970
the DT I-NP I-KP 971,974
synthetic JJ I-NP I-KP 975,984
method, NN I-NP I-KP 985,991
is VBZ I-VP O 993,995
therefore RB I-VP O 996,1005
a DT I-NP O 1006,1007
means NN I-NP I-KP 1008,1013
to TO I-VP I-KP 1014,1016
measure, VB I-VP I-KP 1017,1024
and CC I-VP I-KP 1026,1029
duly VB I-VP I-KP 1030,1034
quantitate VB I-VP I-KP 1035,1045
the DT I-NP I-KP 1046,1049
enantiomeric JJ I-NP I-KP 1050,1062
excess NN I-NP I-KP 1063,1069
– NN I-NP O 1070,1071
signifying VBG I-VP O 1072,1082
the DT I-NP O 1083,1086
degree NN I-NP I-KP 1087,1093
of IN I-PP I-KP 1094,1096
chirality NN I-NP I-KP 1097,1106
within IN I-PP O 1107,1113
molecular JJ I-NP I-KP 1114,1123
products. NN I-NP I-KP 1124,1132

Chiral JJ I-NP I-KP 1134,1140
discrimination NN I-NP I-KP 1141,1155
through IN I-PP O 1156,1163
optical JJ I-NP I-KP 1164,1171
means NNS I-NP I-KP 1172,1177
is VBZ I-VP O 1178,1180
to TO I-VP O 1192,1194
offer VB I-VP O 1195,1200
direct, JJ I-NP O 1201,1207
ways NNS I-NP O 1221,1225
to TO I-VP O 1226,1228
distinguish VB I-VP O 1229,1240
between IN I-PP O 1241,1248
molecules NNS I-NP I-KP 1249,1258
of IN I-PP O 1259,1261
different JJ I-NP O 1262,1271
handedness, NNS I-NP O 1272,1282
based VBN I-VP O 1284,1289
on IN I-PP O 1290,1292
observations NNS I-NP O 1293,1305
such JJ I-NP O 1306,1310
as IN I-PP O 1311,1313
the DT I-NP O 1314,1317
subtle JJ I-NP O 1318,1324
differences NNS I-NP O 1325,1336
in IN I-PP O 1337,1339
absorption NN I-NP I-KP 1340,1350
of IN I-PP O 1351,1353
and CC O O 1360,1363
circularly NN I-NP O 1377,1387
polarised VBN I-VP O 1388,1397
light, NN I-NP O 1398,1403
or CC O O 1405,1407
indeed RB O O 1408,1414
the DT I-NP O 1415,1418
twisting NN I-NP I-KP 1419,1427
of IN I-PP I-KP 1428,1430
polarisation NN I-NP I-KP 1431,1443
in IN I-PP I-KP 1444,1446
optical JJ I-NP I-KP 1447,1454
rotation. NN I-NP I-KP 1455,1463

Other JJ I-NP O 1465,1470
optical JJ I-NP I-KP 1471,1478
methods, NN I-NP I-KP 1479,1486
under IN I-PP O 1488,1493
more RBR I-NP O 1494,1498
recent JJ I-NP O 1499,1505
development, NN I-NP O 1506,1517
also RB O O 1519,1523
show VBP I-VP O 1524,1528
some DT I-NP O 1529,1533
promise NN I-NP O 1534,1541
to TO I-VP O 1542,1544
achieve VB I-VP O 1545,1552
enantiomer NN I-NP I-KP 1553,1563
separation, NN I-NP I-KP 1564,1574
as IN I-PP O 1576,1578
will MD I-VP O 1579,1583
be VB I-VP O 1584,1586
introduced VBN I-VP O 1587,1597
later. NN I-NP O 1598,1603

